Mesalazine-Induced Myopericarditis in a Patient with a Recent Diagnosis of Crohn’s Disease: Apropos of a Case
Mesalazine- (5-aminosalicylic acid-) containing products are a well-known treatment for inflammatory bowel disease, often as first line. Myocarditis is recognized as a very rare possible side effect of this drug treatment. We present a case of mesalazine-induced myopericarditis that was successfully...
Main Authors: | Michele Sorleto, Stefanie Dürrwald, Marcus Wiemer |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2015/728310 |
Similar Items
-
Mesalazine-induced myopericarditis in a patient with ulcerative colitis
by: Jalal Asadi, et al.
Published: (2017-12-01) -
Clinical Efficacy of Oral Mesalazine in Crohn’s Disease
by: Karlernst Maier, et al.
Published: (1990-01-01) -
Accumulation of mesalazine pills in the medium ileum in a patient with Crohn's disease
by: Carmen Martínez-Huertas, et al. -
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
by: Satoshi Tamura, et al.
Published: (2020-12-01) -
Acute myopericarditis
by: Gardiner, A. J. S.
Published: (1975)